Mar 06, 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
Mar 05, 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
Mar 03, 2019
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
Feb 26, 2019
Immutep to Present at Upcoming Industry Conferences
Jan 07, 2019
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
Dec 19, 2018
Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
Nov 27, 2018
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
Nov 11, 2018
Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Oct 31, 2018
Operational Update
Oct 23, 2018
Immutep Announces Data Presentations at Upcoming Industry Conferences
Oct 02, 2018
Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Sep 26, 2018
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
